GUILLERMO GARCIA-MANERO to Hematinics
This is a "connection" page, showing publications GUILLERMO GARCIA-MANERO has written about Hematinics.
Connection Strength
2.418
-
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023 07 29; 402(10399):373-385.
Score: 0.845
-
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood. 2022 01 27; 139(4):624-629.
Score: 0.769
-
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. Leukemia. 2023 11; 37(11):2314-2318.
Score: 0.216
-
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 01 09; 382(2):140-151.
Score: 0.167
-
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase?III?Trial. Clin Lymphoma Myeloma Leuk. 2019 04; 19(4):213-219.e4.
Score: 0.155
-
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 01; 15(1):60-87.
Score: 0.135
-
A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11.
Score: 0.105
-
Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2013 Jul; 11(7):838-74.
Score: 0.027